Loading...
01/11 17:53
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several negative indicators: declining revenue, gross margins, and increased operating losses. Despite some positive elements like service revenue growth and share repurchases, the overall financial performance is weak. The Q&A highlights uncertainties regarding tariffs and funding, and management's unclear responses further exacerbate concerns. The revised revenue outlook and increased losses suggest potential growth challenges. Combined, these factors indicate a likely negative stock price movement in the short term.
Total Revenue $41.5 million, down 7.6% year-over-year; decline driven by weakness in instrument sales in the U.S. and EMEA, partially offset by strength in APAC.
Service Revenue $13.3 million, up 24% year-over-year; growth driven by expansion of the instrument installed base and active usage of tools.
Product Revenue Decreased 18% year-over-year; decline attributed to weaker instrument market in the U.S. and EMEA due to academic funding uncertainties and cautious capital spending.
GAAP Gross Profit $20.2 million, down 12% year-over-year; decline due to lower product revenues and higher manufacturing overhead.
GAAP Gross Margin 49%, down from 51% year-over-year; decline primarily due to lower product revenues.
Non-GAAP Adjusted Gross Margin 52%, down from 55% year-over-year; decline attributed to lower product revenues and higher manufacturing overhead.
Operating Expenses $35.1 million, up $1.4 million year-over-year; increase due to higher general and administrative expenses.
Loss from Operations $15 million, compared to $10.7 million loss in the prior year; larger loss attributed to lower gross profit.
GAAP Net Loss $11.4 million, compared to $6.2 million loss in the prior year; larger loss from operations and a tax expense compared to a tax benefit in the prior year.
Adjusted EBITDA Loss of $3.3 million, compared to a loss of $0.7 million in Q1 of last year; decrease due to lower gross profit.
Total Cash and Marketable Securities $265.6 million, down $12.3 million from Q4; decline primarily driven by $10.6 million share repurchase.
Recurring Revenue 31% of total revenue, up from 26% year-over-year; growth driven by increased service and reagent revenue.
Trailing 12-Month Recurring Revenue Growth 17% year-over-year; reflects growth in service and reagent revenue.
New Product Launch: In the first quarter, Cytek announced the launch of the Cytek Muse Micro System, an affordable flow cytometry option that enhances ease of use, precision, and versatility.
Product Pipeline Investments: Cytek is advancing its product pipeline with newer generations of products, including the Aurora cell sorter and entry-level to mid-level instruments like the Northern Light Line and Muse Micro system.
Market Expansion: Cytek's total revenue in APAC and the rest of the world grew 35.6% year-over-year, reaching $11.4 million, driven by strong demand in these regions.
Geographic Performance: Total U.S. and EMEA revenue declined 13% and 24%, respectively, while Asia Pacific grew 40%, particularly strong in China.
Service Revenue Growth: Service revenue worldwide reached $13.3 million, an increase of 24% versus a year ago, driven by the expansion of the instrument installed base.
Manufacturing Operations: Cytek has established manufacturing operations in the U.S., China, and Singapore, allowing for optimized product flows and enhanced supply chain resilience.
Revenue Outlook Revision: Cytek revised its full year 2025 revenue outlook to a range of $196 million to $210 million, reflecting a growth of -2% to +5% over 2024.
Market Positioning: Cytek maintains a strong competitive position in the FSP market segment, with over 50% of product sales outside the U.S.
Revenue Decline: First quarter revenue decreased by 7.6% year-over-year, primarily due to a decline in instrument sales in the U.S. and EMEA regions.
Academic Funding Uncertainty: In the U.S., uncertainties regarding academic funding due to policy changes have led to a decline in instrument placements.
Government Funding Pressure: In EMEA, government funding priorities have negatively impacted purchasing trends, causing delays in orders.
Cautious Capital Spending: Biotech and Pharma customers are postponing orders due to uncertainties in the industry, affecting overall sales.
Geopolitical and Economic Factors: The company anticipates continued constraints on capital equipment spending in the U.S. and EMEA due to macroeconomic and policy-related factors.
China Market Caution: While there is an increase in orders related to the China stimulus program, the company remains cautious about future sales in China.
Gross Margin Decline: GAAP gross margin decreased to 49% from 51% year-over-year, attributed to lower product revenues and higher manufacturing overhead.
Operating Loss: The company reported a loss from operations of $15 million, an increase from the previous year's loss of $10.7 million.
Revised Revenue Outlook: Due to market changes, the full year 2025 revenue outlook has been revised to a range of $196 million to $210 million, indicating potential growth challenges.
Revenue Growth Strategy: Anticipate full year 2025 revenue to be in the range of $196 million to $210 million, representing overall growth of -2% to +5% over full year 2024.
Market Positioning: Confident in positioning within the large and growing cell analysis market, leveraging industry-leading cell analysis portfolio and global diversification.
Product Development: Launched the Cytek Muse Micro System to enhance accessibility to flow cytometry for smaller labs and resource-limited facilities.
Installed Base Expansion: Expanded global footprint by 115 instruments, bringing total installed base to 3,149 units.
Recurring Revenue Growth: Trailing 12-month recurring revenue grew 17% in Q1, now representing 31% of total revenue, up from 26% a year ago.
Strategic Investments: Investing in product pipeline with newer generations of products, including Aurora cell sorter and Northern Light Line.
Revenue Outlook: Revised full year 2025 revenue outlook to $196 million to $210 million, with growth expected to be back-end loaded to the second half of 2025.
Gross Margin Expectations: Expect quarterly gross margin to improve for the balance of the year as revenue increases consistent with typical seasonal patterns.
Adjusted EBITDA: Expect adjusted EBITDA to improve on a quarterly basis as revenues and gross margins increase.
Capital Expenditure: Current manufacturing capacity can support customer needs without additional capital investment in production facilities.
Share Repurchase Program: Cytek Biosciences repurchased shares worth $10.6 million during Q1 2025.
The earnings call reveals mixed signals. While there is strong growth potential in the reagent business and a strategic focus on innovation, the financial performance is concerning with a net loss and declining EBITDA. The Q&A highlights positive trends in Asia Pacific and biopharma, but challenges in EMEA and U.S. academic sectors persist. The cautious guidance for 2025 and stable U.S. performance balance the negatives, leading to a neutral sentiment rating.
The earnings call reveals mixed signals. While there are positive aspects such as improved net loss, increased service revenue, and strategic product launches, there are concerns about declining revenue, lower gross margins, and uncertainties in academic funding. The Q&A highlights management's cautious optimism, with no clear guidance on macroeconomic impacts. Despite some positive product developments, the overall sentiment remains neutral due to the lack of strong financial performance and clear guidance. The market's reaction is likely to be muted, resulting in a neutral stock price movement.
The earnings call reveals several negative indicators: declining revenue, gross margins, and increased operating losses. Despite some positive elements like service revenue growth and share repurchases, the overall financial performance is weak. The Q&A highlights uncertainties regarding tariffs and funding, and management's unclear responses further exacerbate concerns. The revised revenue outlook and increased losses suggest potential growth challenges. Combined, these factors indicate a likely negative stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
